Bristol-Myers Squibb Co. and Pfizer Inc. on Monday filed a slew of patent infringement suits in Delaware to protect their patents for the successful drug Eliquis and halt the development of generic versions of the profitable blood thinner.
The companies, which jointly develop the drug, targeted at least 13 generic drugmakers in cases filed in the U.S. District Court for the District of Delaware, bringing the total tally to no less than 16. The flurry of litigation kicked off last week with a case filed against Mylan Inc. The new cases were filed Monday and entered to an online docket tracking system Tuesday morning.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
